FDA Approves Ozempic for Type 2 Diabetes

Share this content:
FDA Approves Ozempic for Type 2 Diabetes
FDA Approves Ozempic for Type 2 Diabetes

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- A new once-weekly diabetes medication that lowers blood glucose and also helps patients lose weight has been approved by the U.S. Food and Drug Administration.

The once-a-week injection drug Ozempic (semaglutide) is approved for patients with type 2 diabetes. It stimulates the body's insulin production and reduces appetite, the Associated Press reported.

The drug is from Danish company Novo Nordisk. A company-funded study of 1,200 type 2 diabetes patients found those who took Ozempic had average reductions in long-term blood glucose levels at least 2.5 times greater than those who took daily sitagliptin.

Patients who took Ozempic also lost two to three times as much weight as those in the comparison group, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gender Nonconformity Linked to Students' Mental Distress

Gender Nonconformity Linked to Students' Mental Distress

For male students, gender nonconformity strongly associated with substance use

Participation Up With Online Diabetes Prevention Program

Participation Up With Online Diabetes Prevention Program

But weight loss no different for online, in-person DPP for obese/overweight veterans with prediabetes

Net Benefit of Anticoagulants for A-Fib Varies With Stroke Rate

Net Benefit of Anticoagulants for A-Fib Varies With ...

Benefit of warfarin anticoagulation varies with varying published stroke rates

is free, fast, and customized just for you!




Already a member?

Sign In Now »